Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19390626 | 1.00 | CYP2D6 (0.32) | CYP2D6HRH1KCNH2KDM4EPIK3CD | |
| SCHEMBL16136218 | 1.00 | CYP2D6 (0.32) | CYP2D6HRH1KCNH2KDM4EPIK3CD | |
| SCHEMBL3436793 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL4349290 | 0.86 | PIK3CD (0.37) | CYP2D6HRH1KCNH2KDM4EPIK3CD | |
| SCHEMBL20160904 | 0.84 | KDM4E (0.37) | CYP2D6HRH1KCNH2KDM4EPIK3CD | |
| SCHEMBL24429539 | 0.82 | SLC6A2 (0.35) | KCNH2PIK3CD | |
| SCHEMBL20160908 | 0.82 | PIK3CD (0.34) | CYP2D6HRH1KCNH2KDM4EPIK3CD | |
| SCHEMBL3436790 | 0.81 | PIK3CD (0.37) | CYP2D6HRH1KCNH2PIK3CDPDE7A | |
| SCHEMBL19413248 | 0.80 | PIK3CD (0.40) | CYP2D6HRH1KCNH2PIK3CDCCNT1 | |
| SCHEMBL20749665 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3725314-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-2935214-B1 | 1,4-PYRIDONE COMPOUNDS | EPIZYME INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2935264-B1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | EPIZYME INC (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3022184-B1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20170217941-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-08-03 | — | — | US | disclosed |
| US-9701666-B2 | 1,4-pyridone bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9624205-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160152604-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2016-06-02 | — | — | US | disclosed |
| US-20160031907-A1 | Substituted Benzene Compounds | Epizyme, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-20150344459-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2015-12-03 | — | — | US | disclosed |
| US-9045477-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140296283-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344459-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | CYP4B1, PDXK, CYP1B1 | CYP2D6 25/4885HRH1 1072/4885KCNH2 2354/4885 |
| US-20160031907-A1 | Substituted Benzene Compounds | CYP1B1, CYP4B1, CYP2B6 | CYP2D6 10/4885HRH1 1139/4885KCNH2 1446/4885 |
| US-20140296283-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | CYP2D6 8/4885HRH1 2066/4885KCNH2 2979/4885 |
| US-20160152604-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A5, PAICS | CYP2D6 4/4885HRH1 1579/4885KCNH2 3031/4885 |
| US-20170217941-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | BCOR, CYP2B6, AHR | CYP2D6 7/4885HRH1 732/4885KCNH2 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.